05/04/2023

Hydroxyprogesterone Caproate (Makena) Procedure Code J1726 No Longer a Benefit Effective June 1, 202

Background:

On April 6, 2023, the U.S. Food and Drug Administration (FDA) announced the final decision to withdraw the approval of hydroxyprogesterone caproate (Makena).

Key Details:

Effective June 1, 2023, for dates of service on or after April 6, 2023, hydroxyprogesterone caproate (Makena) procedure code J1726 will no longer be a benefit of Texas Medicaid.

The Texas Medicaid Provider Procedures Manual, *Gynecological, Obstetrics, and Family Planning Title XIX Services Handbook*, subsection 4.1.12, "Hydroxyprogesterone Caproate," and the *Outpatient Drug Services Handbook*, subsection 6.43, "Hydroxyprogesterone Caproate," will be updated to remove references to hydroxyprogesterone caproate.

Affected claims submitted for dates of service from April 6, 2023, through June 1, 2023, may be reprocessed. Affected claims may result in recoupment, which will be reflected on future Remittance and Status (R&S) Reports. No action on the part of the provider is required.

Resources:

The FDA's announcement of its withdrawal of approval for Makena may be found here: https://www.fda.gov/news-events/press-announcements/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena.

Contact:

MedicaidBenefitRequest@hhsc.state.tx.us

Type: Informational

To: CHIP; STAR; STAR+PLUS; STARHEALTH; STAR_KIDS

From: Policy